Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 15/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 15/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 14/20 | 1.00 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.76 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.76 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.76 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13998949 | 0.90 | OPRD1 (0.82) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| SCHEMBL5075460 | 0.90 | OPRD1 (0.82) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| SCHEMBL16810050 | 0.90 | OPRM1 (0.82) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| SCHEMBL16922133 | 0.90 | OPRD1 (0.82) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| SCHEMBL154049 | 0.90 | OPRD1 (0.82) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| SCHEMBL7940016 | 0.90 | OPRD1 (0.82) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| SCHEMBL17302927 | 0.90 | OPRD1 (0.82) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| SCHEMBL29368031 | 0.90 | OPRD1 (0.82) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| SCHEMBL13454098 | 0.90 | OPRD1 (0.82) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| SCHEMBL19107001 | 0.90 | OPRD1 (0.82) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 379 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343784-A1 | TREATMENT OF MEDICATION OVERUSE HEADACHE USING ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES | H LUNDBECK AS (DK) | 2024-10-17 | — | — | US | claimed |
| US-20240209403-A1 | METHODS OF PRODUCING MORPHINAN ALKALOIDS AND DERIVATIVES | HERCULES CAPITAL, INC., AS AGENT | 2024-06-27 | — | — | US | claimed |
| US-20240165110-A1 | SELECTIVE AND NON-SELECTIVE OPIOID RECEPTOR FUNCTIONAL ANTAGONISTS AND METHODS RELATED THERETO FOR TREATMENT OF ADDICTION, OPIOD DEPENDENCE, AND NEUROPATHIC PAIN | TEXAS TECH UNIVERSITY SYSTEM (US) | 2024-05-23 | — | — | US | claimed |
| US-20240165022-A1 | Pharmaceutical Formulation | KLARIA PHARMA HOLDING AB (SE) | 2024-05-23 | — | — | US | claimed |
| US-20240083877-A1 | NOVEL SCAFFOLD OF ADENYLYL CYCLASE INHIBITORS FOR CHRONIC PAIN AND OPIOID DEPENDENCE | PURDUE RESEARCH FOUNDATION (US) | 2024-03-14 | — | — | US | claimed |
| US-11904049-B2 | Pharmaceutical formulation | KLARIA PHARMA HOLDING AB (SE) | 2024-02-20 | — | — | US | claimed |
| US-11884949-B2 | Methods of producing morphinan alkaloids and derivatives | ANTHEIA, INC. (US) | 2024-01-30 | — | — | US | claimed |
| US-20230063876-A1 | Virus-Like Particle Vaccines for Opioid Drugs | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2023-03-02 | — | — | US | claimed |
| US-20220160618-A1 | Pharmaceutical Formulation | KLARIA PHARMA HOLDING AB (SE) | 2022-05-26 | — | — | US | claimed |
| US-20220041562-A1 | NOVEL SELECTIVE KAPPA OPIOID RECEPTOR ANTAGONISTS AND METHODS RELATED THERETO FOR TREATMENT OF ADDICTION AND NEUROPATHIC PAIN | TEXAS TECH UNIVERSITY SYSTEM (US) | 2022-02-10 | — | — | US | claimed |
| WO-2017046581-A1 | COMPOSITION COMPRISING CAV2.2 CALCIUM CHANNEL BLOCKER AND OPIOID | CALCHAN LIMITED (GB) | 2017-03-23 | — | — | WO | claimed |
| EP-3129028-A1 | PHARMACEUTICAL COMPOSITIONS | Charleston Laboratories, Inc. (US) | 2017-02-15 | — | — | EP | claimed |
| CN-106413717-A | Pharmaceutical compositions | 查尔斯顿实验室公司 | 2017-02-15 | — | — | CN | claimed |
| WO-2015157738-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. (US) | 2015-10-15 | — | — | WO | claimed |
| CN-101951921-A | Be used for the treatment of cachectic ways and means | BIONERIS AB | 2011-01-19 | — | — | CN | claimed |
| EP-2187892-A1 | METHOD AND MEANS FOR THE TREATMENT OF CACHEXIA | Bioneris AB (SE) | 2010-05-26 | — | — | EP | claimed |
| WO-2009038533-A1 | METHOD AND MEANS FOR THE TREATMENT OF CACHEXIA | BIONERIS AB (SE) | 2009-03-26 | — | — | WO | claimed |
| WO-2007044229-A2 | SURFACE TREATMENTS FOR CALCIUM PHOSPHATE-BASED IMPLANTS | CALCITEC, INC. (US) | 2007-04-19 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-5352680-A | Administering to humans undergoing opiate administration | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1994-10-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083877-A1 | NOVEL SCAFFOLD OF ADENYLYL CYCLASE INHIBITORS FOR CHRONIC PAIN AND OPIOID DEPENDENCE | CAP1, ADCY1, ADCYAP1R1 | OPRD1 14/4885OPRM1 28/4885OPRK1 11/4885 |
| US-20240165110-A1 | SELECTIVE AND NON-SELECTIVE OPIOID RECEPTOR FUNCTIONAL ANTAGONISTS AND METHODS RELATED THERETO FOR TREATMENT OF ADDICTION, OPIOD DEPENDENCE, AND NEUROPATHIC PAIN | OPRK1, OPRD1, OPRL1 | OPRD1 2/4885OPRM1 4/4885OPRK1 1/4885 |
| US-20220041562-A1 | NOVEL SELECTIVE KAPPA OPIOID RECEPTOR ANTAGONISTS AND METHODS RELATED THERETO FOR TREATMENT OF ADDICTION AND NEUROPATHIC PAIN | OPRK1, OPRD1, OPRM1 | OPRD1 2/4885OPRM1 3/4885OPRK1 1/4885 |
| US-20220160618-A1 | Pharmaceutical Formulation | OGFR, OPRL1, OPRM1 | OPRD1 5/4885OPRM1 3/4885OPRK1 4/4885 |
| US-11904049-B2 | Pharmaceutical formulation | OGFR, OPRL1, OPRM1 | OPRD1 5/4885OPRM1 3/4885OPRK1 4/4885 |
| US-20240165022-A1 | Pharmaceutical Formulation | OGFR, OPRL1, OPRM1 | OPRD1 5/4885OPRM1 3/4885OPRK1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.